An evaluation of GoldAnchor intraprostatic fiducial marker stability during the treatment planning

HTML
DOWNLOAD

Wielkość: px

Rozpocząć pokaz od strony:

Download "An evaluation of GoldAnchor intraprostatic fiducial marker stability during the treatment planning"

Seweryn Kuczyński
9 lat temu
Przeglądów:

1 An evaluation of GoldAnchor intraprostatic fiducial marker stability during the treatment planning Dawid Bodusz, Wojciech Leszczyński, Wioletta Miśta, Leszek Miszczyk Application of fiducial gold markers: prostate liver pancreas Lung Application of gold markers allowed the visualization of the position of the tumor on the X-ray images

Miszczyk Application of fiducial gold markers: prostate liver pancreas Lung

2 tracking IGRT NAL Introduction 2D-2D kv, CB/CT Electronic Portal Image Device IGRT ExacTrac X-Ray X 6D IGRT Image guided radiation tehrapy SonArray- USG 3D MVCT Tomoterapia CyberKnife tracking

3 Purpose The aim of this study was to evaluate of fiducial marker migration inside the prostate during the planning of prostate cancer patients radiotherapy. Material and method: 30 prostate cancer patients radiotherapy technique: IMRT, RapidArc immobilisation system: thermoplastic mask Head First Supine Position (HFS) Dc=76 Gy/g; Df=2,0 Gy/g 2D/2D kv (OBI, Varian Medical Systems) additionally CBCT (OBI, Varian Medical Systems)

Material and method: 30 prostate cancer patients radiotherapy technique: IMRT, RapidArc immobilisation

4 Material and method: 2mm length: mm diameter: 0.28mm Material and method: CBCT

5 Material and method: CBCT Acquisition (A) Full Fan: detector centered 30x40, reconstructed FOV of 24 cm in diameter, 15 cm in C- C extent. (B) Half Fan: detector shifted by 14.8 cm, FOV=45 cm diameter, 14 cm cm c-c extent Material and method: Bow-tie filters

C- C extent. (B) Half Fan: detector shifted by 14.

6 Material and method: CBCT 3, ,0 2,5 2,0 1, ,0 0, Czas Średnia = 31,4583 Średnia±Błąd std = (29,1829, 33,7337) Średnia±Odch.std = (,3112, 42,6055) 0,0-0,5 SI LR AP 3D Mean Mean±SE Mean±SD

7 Średni a 4,5 4,0 3,5 3,5 3,0 3,0 2,5 2,0 2,5 1,5 1,0 SI 2,0 0,5 0,0 1,5-0,5 SI LR AP 3D Średni a±błąd std Średni a±odch.std 1,0 0,5 0,0 Σ = 1,2 mm σ = 0,9 mm -0, pomiar 2,2 2,0 1,8 1,6 3,5 3,0 2,5 1,4 1,2 2,0 1,5 1,0 LR 1,0 0,5 0,8 0,6 0,4 0,2 0,0 0,0-0,5 Średni a Średni a±błąd std Średni a±odch.std SI LR AP 3D Σ = 0,4 mm σ = 0,6 mm -0, pomiar

std 1,0 0,5 0,0 Σ = 1,2 mm σ = 0,9 mm -0,5-5 0 5 10 15 25 30 35 pomiar 2,2 2,0 1,8 1,6 3,5 3,0

8 Średni a 6 5 3,5 3,0 4 2,5 2,0 1,5 3 1,0 0,5 AP 2 0,0-0,5 SI LR AP 3D Średni a±błąd std Średni a±odch.std 1 0 Σ = 1,2 mm σ = 1,2 mm pomiar Direction Mean Minimum Maximum SD AP 1,2 0,0 5,0 1,2 SI 1,2 0,0 4,0 0,9 LR 0,4 0,0 2,0 0,6 3D 2,0 0,0 5,0 1,2 Vector = ( a = x²+y²+z²)

std 1 0 Σ = 1,2 mm σ = 1,2 mm -1-5 0 5 10 15 25 30 35 pomiar Direction

9 The value of migration (mm) Percentage of measurements SI LR AP 3D 0 % (6) 63% (19) 33% (10) 6% (2) 1 50% (15) 30% (9) 37% (11) 47% (14) 2 27% (8) 7% (2) 17% (5) 17% (5) >2 3% (1) 0% (0) 14% (4) 30% (9) CT-CBCT pomiar CT-CBCT Σ = 31 days Min = 9 days Max= 87 days Średnia Średnia±Błąd std Średnia±Odch.std

(9) 100 90 80 70 60 50 46 44 42 40 38 36 34 32 30 28 26 24 CT-CBCT 40 30 10 0-5 0 5 10 15 25 30 35

10 % CT-CBCT pomiar CT-CBCT Σ = 31 days Min = 9 days Max= 87 days Średnia Średnia±Błąd std Średnia±Odch.std CT 6 4 -CT Średnia Średnia±Błąd std Średnia±Odch.std Σ = 12 days Min = 7 days Max= 36 days pom iar

11 R Spearman p SI/time to CT LR/time to CT AP/time to CT 0,53 0,17 0,38 0,002 0,367 0,05 3D/time to CT 0,58 0,000 SI/CT-CBCT CBCT LR/CT-CBCT CBCT AP/CT-CBCT CBCT R Spearman 0,43 0,19 0,31 0,017 0,306 0,095 3D/CT-CBCT CBCT 0,48 0,007 p Conclusion During radiotherapy planning, the intraprostatic fiducial markers can migrate but probably it is not clinically relevant. Because of correlation between time from the implantation to the CBCT and the fiducials migration value, it is reasonable to not delay the radiotherapy start and to control the marker s location during the treatment..

intraprostatic fiducial markers can migrate but probably it is not clinically relevant.

12 Thank you for your attention!!!

Podobne dokumenty

Ocena śródfrakcyjnej ruchomości gruczołu krokowego w trakcie radioterapii chorych na raka stercza

NOWOTWORY Journal of Oncology 2011 volume 61 Number 5 439 443 Ocena śródfrakcyjnej ruchomości gruczołu krokowego w trakcie radioterapii chorych na raka stercza Dawid Bodusz, Grzegorz Głowacki, Leszek Miszczyk